Pfizer has a long tradition of innovation and investments in Belgium. Across four internationally renowned Belgian sites, Pfizer’s presence ticks nearly all boxes of the innovation process of a medicine or vaccine: from Phase 1 clinical research in Anderlecht over aseptic manufacturing and packaging of injectables in Puurs to the global distribution of medicines and vaccines in Zaventem.
Pfizer manufacturing plant in Puurs
Some could say Pfizer has what French-speakers call a ‘coup de foudre’ for Belgium: love at first sight, with its well-anchored and continual investment in Belgium since 1952. Karel Van De Sompel (Country Manager, Pfizer Belgium) explains: “Belgium is known to have a unique ecosystem for the pharmaceutical sector. All elements for a fruitful business can be found here: a talented and highly educated and productive workforce, world-class researchers, top-notch academic centers, an excellent healthcare system, several innovation hubs, a vibrant start-up and scale-up community… You name it, Belgium seems to have it.”
The booming manufacturing and packaging operations in the Puurs site near Antwerp have drawn in sustained large investments and increasing number of employees. Pfizer’s Zaventem logistics center supplies medicines and vaccines all over the world, thanks to Belgium’s international airports and ports and its dense road network.
In Anderlecht, Pfizer is dedicated to advancing new treatments through their Clinical Research Unit. They work on breakthroughs that change patients’ lives and strive to continually contribute to the unique Belgian pharmaceutical ecosystem.
Inside Pfizer in Puurs
Belgium has developed into a ‘pharma valley’, offering an attractive ecosystem for pharmaceutical companies to say yes to Belgium. Pfizer said yes over six decades ago, and the relationship is still alive and kicking. As Luc Van Steenwinkel (Managing Director, Pfizer Puurs) explains, “We are proud of our footprint in Belgium. Our American headquarters appreciate our expertise and consider us to be a trusted partner in Pfizer’s international supply network. Their trust translates in continued investments, although these are not a given. Every day, we work hard to earn and honor that trust. A stable and competitive economical and entrepreneurial environment is essential to secure future investments too. Although we supply medicines and vaccines to countries all over the world – including developing countries – we still need a strong Belgian foundation to build our operations on.”
Research and development at Pfizer in Puurs